Vascugen is a biotechnology company developing regenerative medicine for treatment of intractable vascular diseases.
Vascugen is an induced pluripotent stem cell (iPSC) therapy company advancing its novel vasculogenic cell technology to develop and manufacture engineered vascular cells. Our vasculogenic cells have the potential to directly address ischemic disease conditions and to serve as a novel platform for delivery of therapeutic payloads in cardiovascular, solid tumor, and other indications. Vascugen’s research and development facility includes an integrated manufacturing facility for early-stage clinical manufacture of our products.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 16, 2018 | Pre-seed | $835K | 1 | Indiana University Philanthropic Venture Fund | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Indiana University Philanthropic Venture Fund | Yes | Pre-seed |